• Explore /
  • Poster
  • / KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.

Abstract Poster

Authors

null

Jacob Sands

Dana-Farber Cancer Institute, Boston, MA

Jacob Sands , Martin Reck , Alejandro Navarro , Anne C. Chiang , Shun Lu , Nir Peled , Luis G. Paz-Ares , Samuel J. Kerr , Toshiaki Takahashi , Alexey Smolin , Xinqun Chen , Bin Zhao , Hazem Edmond El-Osta , Raffaele Califano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05224141

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS8606)

DOI

10.1200/JCO.2022.40.16_suppl.TPS8606

Abstract #

TPS8606

Poster Bd #

223a

Abstract Disclosures

Similar Posters

First Author: Dawei Chen

First Author: Andreas Rimner

First Author: Yuanbin Chen

First Author: Leora Horn